Sugentech Inc (253840) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sugentech Inc (253840) has a cash flow conversion efficiency ratio of -0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.25 Billion ≈ $-2.88 Million USD) by net assets (₩72.28 Billion ≈ $48.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sugentech Inc market capitalisation for the company's overall valuation and market capitalisation.
Sugentech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sugentech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sugentech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sugentech Inc ranked by their cash flow conversion efficiency. Explore Sugentech Inc (253840) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ashmore Asset Management Indonesia
JK:AMOR
|
0.001x |
|
Unigold Inc.
V:UGD
|
-0.698x |
|
Changhae Ethanol Co. Ltd
KQ:004650
|
0.102x |
|
Simula Technology
TWO:3511
|
0.013x |
|
Francotyp-Postalia Holding AG
F:FPH
|
0.005x |
|
East Asia Holdings Investment Limited
KQ:900110
|
0.031x |
|
Clene Inc.
NASDAQ:CLNN
|
0.104x |
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
0.338x |
Annual Cash Flow Conversion Efficiency for Sugentech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sugentech Inc from 2017 to 2025. View 253840 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩76.54 Billion ≈ $51.87 Million |
₩-14.65 Billion ≈ $-9.93 Million |
-0.191x | -147.24% |
| 2024-12-31 | ₩97.13 Billion ≈ $65.82 Million |
₩-7.52 Billion ≈ $-5.09 Million |
-0.077x | +28.39% |
| 2023-12-31 | ₩112.45 Billion ≈ $76.21 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.108x | -149.93% |
| 2022-12-31 | ₩140.58 Billion ≈ $95.27 Million |
₩30.43 Billion ≈ $20.62 Million |
0.216x | -44.04% |
| 2021-12-31 | ₩100.71 Billion ≈ $68.25 Million |
₩38.96 Billion ≈ $26.40 Million |
0.387x | +67.51% |
| 2020-12-31 | ₩63.11 Billion ≈ $42.77 Million |
₩14.57 Billion ≈ $9.87 Million |
0.231x | +239.92% |
| 2019-12-31 | ₩24.31 Billion ≈ $16.47 Million |
₩-4.01 Billion ≈ $-2.72 Million |
-0.165x | +18.61% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.47 Million |
₩-3.13 Billion ≈ $-2.12 Million |
-0.203x | -831.42% |
| 2017-12-31 | ₩-32.81 Billion ≈ $-22.24 Million |
₩-909.59 Million ≈ $-616.42K |
0.028x | -- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more